8-K
filed May 7, 2026, 7:59 PM ET
ticker GH
CIK 0001576280
earnings
confidence high
sentiment positive
materiality 0.80
Guardant Health Q1 revenue rises 48% to $301.7 million, boosts 2026 guidance
Guardant Health, Inc.
2026-Q1 EPS reported
-$0.85
revenue$301,665,000
- Revenue increased 48% to $301.7M driven by Oncology revenue growth of 36% and Screening revenue surge to $41.6M.
- Net loss per share widened to $0.85 from $0.77; non-GAAP net loss per share improved to $0.45 from $0.49.
- Raised 2026 revenue guidance to $1.30-$1.32B (32-34% growth), up from prior $1.25-$1.28B; Oncology volume growth expected >35%.
- Shield screening tests reached 44,000 in Q1; 2026 Shield volume guidance raised to 230,000-245,000 tests.
- Q1 adjusted EBITDA loss of $58.9M relatively flat; free cash flow burn $71.2M; cash position $1.2B.
Machine-readable event card
- schema_version
- secwatch.filing_event.v1
- accession
- 0001576280-26-000024
- form_type
- 8-K
- ticker
- GH
- cik
- 0001576280
- company_name
- Guardant Health, Inc.
- filed_at
- 2026-05-07T23:59:59+00:00
- discovered_at
- 2026-05-14T18:02:32.499602+00:00
- generated_at
- 2026-05-14T21:41:55.645779+00:00
- sec_items
- ["2.02", "9.01"]
- event_type
- earnings
- sentiment
- positive
- materiality_score
- 0.8
- calibrated_materiality_score
- 0.8
- confidence
- high
- secwatch_canonical_url
- https://secwatch.observer/filing/0001576280-26-000024
- json_url
- https://secwatch.observer/filing/0001576280-26-000024.json
- markdown_url
- https://secwatch.observer/filing/0001576280-26-000024.md
- text_url
- https://secwatch.observer/filing/0001576280-26-000024.txt
- edgar_index_url
- https://www.sec.gov/Archives/edgar/data/1576280/000157628026000024/0001576280-26-000024-index.htm
- edgar_primary_document_url
- https://www.sec.gov/Archives/edgar/data/1576280/000157628026000024/gh-20260507.htm
- generated_by_model
- deepseek-v4-flash:cloud@v2
- review_status
- machine_generated
- human_reviewed
- false
- corrected
- false
- correction_note
- null
- correction_timestamp
- null
- superseded_by
- null
Comparable filings
GMRS
GMR Solutions Q1 revenue $1.46B (+6.6% YoY), net income $106M (+180% YoY), guides FY26 rev $5.9-6.2B
GMR Solutions Inc.
June 1, 2026, 4:45 PM ET
earnings
Items 2.02, 9.01
same fact type: earnings_release
same SEC item: 2.02, 9.01
same event type: earnings
similar materiality
This filing
March 31, 2026. First Quarter 2026 Financial Highlights For the three-month period ended March 31, 2026, as compared to the same period of 2025: • Reported total revenue of $301.7 million, an increase of 48%, driven by: ◦ Oncology revenue of $205.0 million, an increase of 36%, and approximately 86,000 oncology tests, an increase of 47% ◦ Biopharma & Data revenue
Comparable filing
today announced financial results for the first quarter ended March 31, 2026, and full year 2026 financial guidance. First Quarter 2026 Financial Highlights ● Net revenue of $1,457.6 million, up 6.6% compared to $1,367.4 million in the first quarter of 2025 ● Net income of $106.3 million, up 179.7% compared to $38.0 million in the first quarter of 2025 ● Adjusted
Filing page
SEC filing
HPE
HPE Q2 FY26: record revenue $10.7B (+40%), raises FY26 guidance, introduces FY27 framework
Hewlett Packard Enterprise Co
June 1, 2026, 4:09 PM ET
earnings
Items 1.01, 2.02, 5.02, 7.01, 9.01
same fact type: earnings_release
same SEC item: 2.02, 9.01
same event type: earnings
similar materiality
This filing
March 31, 2026. First Quarter 2026 Financial Highlights For the three-month period ended March 31, 2026, as compared to the same period of 2025: • Reported total revenue of $301.7 million, an increase of 48%, driven by: ◦ Oncology revenue of $205.0 million, an increase of 36%, and approximately 86,000 oncology tests, an increase of 47% ◦ Biopharma & Data revenue
Comparable filing
gross margin, and non-GAAP diluted net EPS, as well as its highest-ever free cash flow generation for a second quarter. Second Quarter Fiscal 2026 Financial Results • Revenue : $10.7 billion, up 40% from the prior-year period • Gross margins : ◦ GAAP of 36.5%, up 810 basis points from the prior-year period and up 60 basis points sequentially ◦ Non-GAAP (1) of 36.9%,
Filing page
SEC filing
CRDO
Credo Q4 revenue $437M (+157% YoY); guides Q1 $465-475M; CEO awarded 1.44M performance-based RSUs
Credo Technology Group Holding Ltd
June 1, 2026, 4:08 PM ET
earnings
Items 2.02, 5.02, 9.01
same fact type: earnings_release
same SEC item: 2.02, 9.01
same event type: earnings
similar materiality
This filing
March 31, 2026. First Quarter 2026 Financial Highlights For the three-month period ended March 31, 2026, as compared to the same period of 2025: • Reported total revenue of $301.7 million, an increase of 48%, driven by: ◦ Oncology revenue of $205.0 million, an increase of 36%, and approximately 86,000 oncology tests, an increase of 47% ◦ Biopharma & Data revenue
Comparable filing
On June 1, 2026, Credo Technology Group Holding Ltd (the "Company") issued a press release announcing its financial results for the fiscal year ended May 2, 2026.
Filing page
SEC filing
DAVEY TREE EXPERT CO
Davey Tree Q1 net loss widens to $10.7M; revenue flat at $435.8M
DAVEY TREE EXPERT CO
June 1, 2026, 1:50 PM ET
earnings
Items 2.02, 9.01
same fact type: earnings_release
same SEC item: 2.02, 9.01
same event type: earnings
similar materiality
This filing
March 31, 2026. First Quarter 2026 Financial Highlights For the three-month period ended March 31, 2026, as compared to the same period of 2025: • Reported total revenue of $301.7 million, an increase of 48%, driven by: ◦ Oncology revenue of $205.0 million, an increase of 36%, and approximately 86,000 oncology tests, an increase of 47% ◦ Biopharma & Data revenue
Comparable filing
Exchange Act, unless such subsequent filing specifically references this Form 8-K.
--- EX-99.1 (EX-99.1) ---
To Our Shareholders, The Company’s first quarter 2026 revenue of $435.8 million increased slightly from the record first quarter 2025 revenue by $1.0 million, or 0.2%. This growth was driven by consistent demand in the Utility segment, where revenue
Filing page
SEC filing
URG
Ur-Energy Q1 2026: pounds captured up 41% QoQ, avg price $70.98, Shirley Basin commenced
UR-ENERGY INC
May 11, 2026, 7:59 PM ET
earnings
Items 2.02, 9.01
same fact type: earnings_release
same SEC item: 2.02, 9.01
same event type: earnings
similar materiality
This filing
March 31, 2026. First Quarter 2026 Financial Highlights For the three-month period ended March 31, 2026, as compared to the same period of 2025: • Reported total revenue of $301.7 million, an increase of 48%, driven by: ◦ Oncology revenue of $205.0 million, an increase of 36%, and approximately 86,000 oncology tests, an increase of 47% ◦ Biopharma & Data revenue
Comparable filing
a 14% increase over Q4 2025 and a 13% increase over Q1 2025. Financial Performance ◾ Contracted Sales: We sold 55,000 produced pounds of U 3 O 8 as anticipated, generating $3.9 million in revenue, with a majority of our 2026 deliveries scheduled for the latter part of the year to complement the ramp-up and start-up schedules of Lost Creek and Shirley Basin. ◾
Filing page
SEC filing
ACH
Accendra Health Q1 revenue $627.8M, adj. EBITDA $58.4M; >$1.5B debt optimization
ACCENDRA HEALTH INC/VA/
May 11, 2026, 7:59 PM ET
earnings
Items 2.02, 7.01, 9.01
same fact type: earnings_release
same SEC item: 2.02, 9.01
same event type: earnings
similar materiality
This filing
March 31, 2026. First Quarter 2026 Financial Highlights For the three-month period ended March 31, 2026, as compared to the same period of 2025: • Reported total revenue of $301.7 million, an increase of 48%, driven by: ◦ Oncology revenue of $205.0 million, an increase of 36%, and approximately 86,000 oncology tests, an increase of 47% ◦ Biopharma & Data revenue
Comparable filing
Commission this morning. Details on First Quarter 2026 Results First Quarter Results (1) ($ in millions, except per share data) 1Q26 1Q25 Net Revenue $ 627.8 $ 673.9 Loss from continuing operations, net of tax, GAAP $ (6.5) $ (3.8) Adj. net (loss) income from continuing operations, Non-GAAP $ (3.1) $ 23.2
Filing page
SEC filing
LQDA
Liquidia Q1 2026 net income $53M vs $38M loss YoY; YUTREPIA sales $130M
Liquidia Corp
May 11, 2026, 7:59 PM ET
earnings
Items 2.02, 8.01, 9.01
same fact type: earnings_release
same SEC item: 2.02, 9.01
same event type: earnings
similar materiality
This filing
March 31, 2026. First Quarter 2026 Financial Highlights For the three-month period ended March 31, 2026, as compared to the same period of 2025: • Reported total revenue of $301.7 million, an increase of 48%, driven by: ◦ Oncology revenue of $205.0 million, an increase of 36%, and approximately 86,000 oncology tests, an increase of 47% ◦ Biopharma & Data revenue
Comparable filing
First Quarter 2026 Financial Results YUTREPIA sales led to the company’s third consecutive quarter of profitability with net income of $52.9 million and positive non-GAAP adjusted EBITDA of $71.2 million in the first quarter of 2026. Cash and cash equivalents totaled $222.8 million as of March 31, 2026, compared to $190.7 million as of December 31, 2025. Product sales, net, were $129.9 million for the three months ended March 31, 2026.
Filing page
SEC filing
TH
Target Hospitality Q1 revenue up 4% but net loss widens to $13M; announces $750M AI infrastructure contract
Target Hospitality Corp.
May 11, 2026, 7:59 PM ET
earnings
Items 2.02, 9.01
same fact type: earnings_release
same SEC item: 2.02, 9.01
same event type: earnings
similar materiality
This filing
March 31, 2026. First Quarter 2026 Financial Highlights For the three-month period ended March 31, 2026, as compared to the same period of 2025: • Reported total revenue of $301.7 million, an increase of 48%, driven by: ◦ Oncology revenue of $205.0 million, an increase of 36%, and approximately 86,000 oncology tests, an increase of 47% ◦ Biopharma & Data revenue
Comparable filing
today reported results for the three months ended March 31, 2026. Financial Highlights for the quarter ended March 31, 2026 ● Revenue of $72.8 million. ● Net loss of ($13.0) million. ● Basic and diluted loss per share of $0.13 . ● Adjusted EBITDA (1) of $9.9 million. ● Net Cash Provided by Operating Activities of $7.0 million and Discretionary Cash
Filing page
SEC filing
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.